June 15, 2020 / 4:39 PM / 20 days ago

BRIEF-Provention Bio's Teplizumab Continued To Delay The Onset Of Insulin-Dependent Type 1 Diabetes

June 15 (Reuters) - Provention Bio Inc:

* PROVENTION BIO’S TEPLIZUMAB CONTINUED TO SIGNIFICANTLY DELAY THE ONSET OF INSULIN-DEPENDENT TYPE 1 DIABETES (T1D) IN PRESYMPTOMATIC PATIENTS

* PROVENTION BIO INC - ONE COURSE OF TEPLIZUMAB NOW SHOWN TO DELAY INSULIN-DEPENDENT T1D BY A MEDIAN OF APPROXIMATELY 3 YEARS

* PROVENTION BIO INC - TEPLIZUMAB SIGNIFICANTLY REVERSED DECLINE IN C-PEPTIDE LEVELS

* PROVENTION BIO INC - TEPLIZUMAB WAS WELL TOLERATED AND SAFETY DATA IS CONSISTENT WITH PREVIOUS ANALYSES

* PROVENTION BIO INC - ON TRACK TO COMPLETE BIOLOGICS LICENSE APPLICATION SUBMISSION FOR TEPLIZUMAB Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below